Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol

Published:2012-07-27 Issue:8 Volume:64 Page:2529-2536
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis & Rheumatism

Author:

Stamp Lisa K.,Taylor William J.,Jones Peter B.,Dockerty Jo L.,Drake Jill,Frampton Christopher,Dalbeth Nicola

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/art.34488/fullpdf

Reference30 articles.

1. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy;Shoji;Arthritis Rheum,2004

2. Influence of antihyperuricemic therapy on the clinical and radiographic progression of gout;McCarthy;Arthritis Rheum,1991

3. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout;Perez-Ruiz;Arthritis Rheum,2002

4. Quality of care indicators for gout management;Mikuls;Arthritis Rheum,2004

5. EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT);Zhang;Ann Rheum Dis,2006

Cited by 248 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of gout treatments in people with renal impairment;Exploration of Musculoskeletal Diseases;2024-09-02

2. Easing the way to achieving target serum urate in people with gout: protocol for a non-inferiority randomised strategy trial using an allopurinol dosing model in Aotearoa/New Zealand (the Easy-Allo Study);BMJ Open;2024-08

3. La gota, más allá de la articulación: ¿cómo debemos tratarla?;Medicina de Familia. SEMERGEN;2024-07

4. Yet More Reassurance: Treat-to-Target With Allopurinol or Febuxostat is Safe and Effective in Lowering Serum Urate in People With CKD;American Journal of Kidney Diseases;2024-07

5. Efficacy and Safety of Allopurinol and Febuxostat in Patients With Gout and CKD: Subgroup Analysis of the STOP Gout Trial;American Journal of Kidney Diseases;2024-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3